tirzepatide shortage fda news confirms is still over, gives compounders a grace period Tirzepatide is NO longer in – Zepbound, Mounjaro shortages are resolved,

Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine and an investigator in multiple obesity pharmacotherapy trials, has stated: "Triple-receptor agonists represent the next frontier

Tirzepatide specifically acts on both GLP-1 and GIP receptors, which is why it has shown even stronger weight loss results than single-receptor agonists like semaglutide in clinical trials

Pharma companies must carefully navigate this landscape to ensure timely launches while meeting compliance standards

Genetic variants associated with stronger GLP-1 receptor activity, for example, may correlate with more pronounced initial metabolic shiftspotentially affecting hydration status and hemoglobin levels relevant to plasma donation screening

These supplements are often promoted in pharmacies, online, and through social media as natural alternatives that can increase satiety, improve metabolism, or support weight loss